stockrowConnect Biopharma Holdings Limited Sponsored ADR
CNTBConnect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024.
- Revenue
- +296.6%
- EPS
- −17.4%
- Free cash flow
- −23.5%
- Total debt
- −61.0%
Quarter to June 2026, against a year earlier
Follow CNTB
Alert me
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Return on invested capital
Connect Biopharma Holdings Limited Sponsored ADR's return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −1,401.7% (fiscal 2022) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 1,401.74 |
| FY2022 | −1,401.7% | (46.39) |
| FY2021 | −1,355.4% | (1,355.35) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | 0.00% |
| CRBU Caribou Biosciences, Inc. compare | 0.00% |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | 0.00% |
| ELTX Elicio Therapeutics, Inc. compare | 0.00% |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | 0.00% |
| SGMOQ Sangamo Therapeutics, Inc. compare | 0.00% |
| TELO Telomir Pharmaceuticals, Inc. compare | 0.00% |
| TIL Instil Bio, Inc. compare | −18.9% |
| IMA ImageneBio, Inc. compare | −2,031.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)